Genflow Biosciences plc
GENF.L · LSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | – | – | – | £4,183 |
| - Cash | £279 | £279 | £279 | £684 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | – | – | – | £3,499 |
| Revenue | £123 | £123 | -£396 | -£97 |
| % Growth | 0% | 130.9% | -308.2% | – |
| Gross Profit | £123 | £123 | -£396 | -£98 |
| % Margin | 100% | 100% | 100% | 100.6% |
| EBITDA | -£369 | -£369 | -£531 | -£982 |
| % Margin | -300.7% | -300.7% | 134.1% | 1,012.5% |
| Net Income | -£369 | -£369 | -£531 | -£1,007 |
| % Margin | -300.9% | -300.9% | 134.2% | 1,038% |
| EPS Diluted | -0.001 | -0.001 | -0.002 | -0.003 |
| % Growth | 0% | 33.3% | 55.9% | – |
| Operating Cash Flow | -£418 | -£418 | -£442 | -£811 |
| Capital Expenditures | £0 | £0 | £0 | £2 |
| Free Cash Flow | -£418 | -£418 | -£441 | -£809 |